chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Swollen gland under arm; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP).  A male patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose number unknown, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: LYMPHADENOPATHY (non-serious), outcome "unknown", described as "Swollen gland under arm".  Additional information-This report is in reference to one of the two guys reporters husband went with to get his Covid 19 vaccine. While speaking of her husband's experience with the Covid 19 vaccine, she mentions that two other guys her husband went with on the same day to get their Covid 19 vaccines,  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
post menopausal bleeding    spotting after first 2 Pfizer vaccines administered in April 2021 and a full on regular menstrual period after Moderna booster in late November 2021
the vaccine caused me to get bells palsy the right side of my face sagging and difficult speech right eye not closing very well
Felt like throat was closing.  VS stable,  O2 sats 99%,  Symptoms resolved within 5 minutes
malaise; soreness; two doses of Shingrix; This case was reported by a pharmacist via call center representative and described the occurrence of malaise in a 56-year-old male patient who received Herpes zoster (Shingrix) (batch number 39KB3, expiry date 11th April 2022) for prophylaxis.   On 1st February 2020, the patient received Shingrix. On 1st February 2020, unknown after receiving Shingrix, the patient experienced overdose. On an unknown date, the patient experienced malaise and pain. On an unknown date, the outcome of the malaise, pain and overdose were unknown.   It was unknown if the reporter considered the malaise and pain to be related to Shingrix.  Additional details were reported as follows: The age at vaccination was not reported. On the same day the patient received two doses of Shingrix, which led to overdose. HCP reports less than a week after vaccination, the patient experienced malaise and soreness following administration of 2 doses of Shingrix at the same visit. Only one suspect coded as it was given on same day.
After given 4th vaccine, he became pale and laid head on arm-passed out and then immediately tensed/convulsed about 3 seconds. Mom reported (via translator) symptoms usual after vaccines-always happens and not new symptoms. Reported after vaccines given. Cold pack applied to back, head down between knees. Vitals checked, monitored, snack and water. 1035 BP-110/80 HR-76 R-16 T-97%.
Cellulitis of the arm at injection site. Red, hot, swollen, tender over most of the left upper arm.
Myalgia tingling and paresthesia of mouth, tongue , scratchy throat, mild cough, metallic taste, myalgia Narrative:  tingling and paresthesia of mouth, tongue , scratchy throat, mild cough, metallic taste, myalgia
This spontaneous report as received from a registered nurse via company representative refers to a 18 year old male patient. There was no patient's concurrent conditions and medical history reported. Concomitant therapies included Tdap (unspecified), meningococcal vaccine (unspecified) and Hep A vaccine (unspecified). Approximately in 2015 (reported as last few weeks), the patient experienced lightheadedness, five minutes after receiving GARDASIL 9 lot # K026247, expiration date unknown, (dose was unknown) intramuscularly. The patient did not receive treatment. The patient did not seek medical attention. The outcome of event was reported as recovered on an unspecified date in 2015. The relatedness between the event and GARDASIL 9 was not reported. This is one of several reports from the same source. Additional information has been requested.
24 hours post vaccines, pt had pronounced redness from elbow to shoulder with slight swelling. Pt had mild and worsening pain in shoulder with nausea. Got prednisone inj. at urgent care and resolved within 10 min.
Patient started having chest pain which increased over two days. Patient was seen in ER on 02/08/2016 at 12:00 Noon and diagnosed with mild case myocarditis.
Admitted to hospital in acute kidney and liver failure.  Pre-existing conditions but not advanced.  Only change in routine was vaccine.   Still in hospital trying to diagnose cause and get organs functioning correctly.
I woke up Tuesday with eye feeling very irritated. By night time it was so bad I couldn't sleep. I went to the eye doctor and she told me I could have internal uveitis and a severe allergic reaction gave me something she prescribed a steroid and then it got better and the swollen is gone and the irritation is almost gone. I went back to the doctors today to get rechecked and she said it confirmed that it got way better.
Redness 1 day later Calamine lotion, Tylenol if any pain, appt next day for follow up.
Dark brown urine, which lasted for 8 days.  Temperature of 102 for 48 hours.  Vomiting and weakness 3 days.
went to bed for a couple of days; Tired/wiped out; This spontaneous case was reported by a nurse and describes the occurrence of BEDRIDDEN (went to bed for a couple of days) and FATIGUE (Tired/wiped out) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 031A21A and 032M20A) for COVID-19 prophylaxis.     No Medical History information was reported.   On 06-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 03-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 03-Apr-2021, the patient experienced BEDRIDDEN (went to bed for a couple of days) and FATIGUE (Tired/wiped out). In April 2021, BEDRIDDEN (went to bed for a couple of days) had resolved. At the time of the report, FATIGUE (Tired/wiped out) outcome was unknown. For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported.  No treatment medications were reported.   This case was linked to MOD-2022-663083, MOD-2022-663104, MOD-2022-663113, MOD-2022-663126 (Patient Link).
developed a fever; This is a spontaneous report from a contactable consumer, the patient. A 31-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0168) via an unspecified route of administration in the left arm on 14May2021 at 09:30 (at the age of 31-years-old) as a single dose for COVID-19 immunisation. Medical history was reported as none. The patient had no allergies to medications, food, or other products. Concomitant medications included ibuprofen (ADVIL), taken from an unknown date for an unspecified indication. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 23Apr2021 at 09:30 (at the age of 31-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 14May2021 at 19:30, about 10 hours after vaccination, the patient developed a fever that got up to over 104 degrees. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the event fever was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Headache; vertigo; nausea; body aches; chills; This is a spontaneous report from a contactable consumer (patient). A 52-years-old non-pregnant female patient who received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/lot: EK9261, Expiration date unknown), via an unspecified route of administration in right arm on 27Jan2021 at 12:30, 2ND DOSE, SINGLE for covid-19 immunization (at the age of 52 years). The patient previously received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/lot: EK9231, Expiration date unknown), via an unspecified route of administration in left arm on 06Jan2021 at 11:30, at a single dose for covid-19 immunization on (at the age of 52 years) in hospital. Patient's medical history included rheumatoid arthritis and fibromyalgia. Patient's concomitant medications included doxepin, pregabalin, sulfasalazine, and celecoxib (CELEBREX). The patient had penicillin allergy to medications, food, or other products. The patient was not diagnosed with COVID-19 prior to vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Since the vaccination, the patient was not tested for COVID-19. On 27Jan2021 at 14:30, the patient experienced headache, vertigo, nausea, body aches, and chills. The patient did not receive any treatment. The outcome of events was recovering.  Follow-up attempts are completed. No further information is expected.
fever 104 w/APAP x 6 hrs; cried 2-3 hrs inconsolable; refused to move head or extremities 2-3 hrs p/inject;
Administration of vaccine past published expiry; The vaccine were thawed on the day of administration and administration was spread out throughout the end of March to the beginning of April; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Administration of vaccine past published expiry) and PRODUCT STORAGE ERROR (The vaccine were thawed on the day of administration and administration was spread out throughout the end of March to the beginning of April) in a 36-year-old male patient who received mRNA-1273 (Spikevax) (batch no. 059H21A) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On an unknown date, the patient experienced EXPIRED PRODUCT ADMINISTERED (Administration of vaccine past published expiry) and PRODUCT STORAGE ERROR (The vaccine were thawed on the day of administration and administration was spread out throughout the end of March to the beginning of April). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Administration of vaccine past published expiry) and PRODUCT STORAGE ERROR (The vaccine were thawed on the day of administration and administration was spread out throughout the end of March to the beginning of April) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported.  The first dose details were not asked. The vaccine was thawed on the day of administration and administration was spread out throughout the end of March to the beginning of April.  The vial was initially stored in the refrigerator on 01Apr2022/thawed on the day of use. 19 patients were administered on 29Mar2022, 30Mar2022, 31Mar2022, 01Apr2022 and 04Apr2022. The vial did not undergo any temperature excursions.  No treatment medications were reported.
Information has been received from a medical assistant concerning a patient (age not specified) who on unspecified date was vaccinated intramuscularly with pneumococcal 23v polysaccharide vaccine.  It was unknown if the patient received the vaccination in the leg.  On an unspecified date, the patient developed a "red, painful, local reaction after receiving pneumococcal 23v polysaccharide vaccine".  The patient sought unspecified medical attention.  It was reported that "as a result of those reactions the office was going to give all future pneumococcal 23v polysaccharide vaccine subcutaneously".  At the time of this report, the patient had recovered from the events (date unknown).  Additional information is not expected.
Needle stick by the person administering  the vaccine to herself while putting the used syringe in the sharps container.
Syncope; Tachycardia; This case was reported by a nurse via sales rep and described the occurrence of syncope in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced syncope (serious criteria GSK medically significant) and tachycardia. On an unknown date, the outcome of the syncope and tachycardia were recovered/resolved.   The reporter considered the syncope and tachycardia to be related to Shingrix.  Additional information was received as follows: The age at vaccination was not reported. The patient was monitored. The patient was okay. The reporter agreed to follow up contact.
Patient began losing significant weight in weeks following vaccine and was formally diagnosed on 3/15/22 with Type 1 Diabetes.
Very ill with flu-like sx in days following vaccine.  Pressure in ears with increased hearing causing headache persisting >3 weeks.
Got Flu like symptoms; Felt extremly dizzy; Fell at night; This spontaneous case was reported by a consumer and describes the occurrence of INFLUENZA LIKE ILLNESS (Got Flu like symptoms), DIZZINESS (Felt extremly dizzy) and FALL (Fell at night) in an 81-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 006M20A and unknown) for COVID-19 vaccination.     No Medical history was provided by the reporter.    In January 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 19-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 19-Feb-2021, the patient experienced INFLUENZA LIKE ILLNESS (Got Flu like symptoms), DIZZINESS (Felt extremly dizzy) and FALL (Fell at night). On 20-Feb-2021, INFLUENZA LIKE ILLNESS (Got Flu like symptoms), DIZZINESS (Felt extremly dizzy) and FALL (Fell at night) had resolved.            No relevant concomitant medications reported. Treatment details included OTC medications.   This case was linked to MOD-2021-025792, MOD-2021-027818 (Patient Link).
Headache fatigue, malaise Narrative:  Per supervisor report: "received second vaccine on 3/23/2021-migraine, sore arm, exhausted, feels life she is catching a cold"
POSITIVE SCREEN FOR COVID 12/17/21.  PRESENTED TO EMERGENCY DEPARTMENT FOR EVALUATION OF SHORTNESS OF BREATH. ADMITTED 12/30/21 HOSPITAL COURSE: Patient is a 86 y.o. female with lymphoma in remission and recent diagnosis of Alzheimer's dementia. She was fully vaccinated for Covid including booster.  Came in with hypoxia from PCP office in setting of prior Covid positive test.  CXR consistent with pneumonia but also elevated procalcitonin with leukocytosis made concomitant bacterial pneumonia likely.  Elevated D-dimer but CTA was negative for PE.  Admit also with elevated lactic acid.  Initially started on Decadron, Lovenox with dose based on institutional protocol, started on cefuroxime and doxycycline for CAP coverage, cautiously volume repleted, provided supplemental oxygen.  Did have a downtrend in her procalcitonin which led us to believe that her CAP was being adequately treated. Unfortunately abrupt decline early morning 1/4 requiring BiPAP w/ 100% Fi02 felt to be from worsening of her Covid pneumonia.  After discussion with family was placed on comfort cares.  Palliative care was consulted, appreciate their support.  She was aggressively symptomatically managed until she passed in the hospital yesterday evening surrounded by her family. CAUSE OF DEATH:  Acute hypoxic respiratory failure suspect from Covid pneumonia
aching in her bones; muscle pain; joint pain; This is a spontaneous report from a contactable consumer (patient) via medical information team from a Pfizer sponsored program. A 73-years-old female patient reported for herself that she received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Batch/Lot Number: FA6780, Expiry date: Unknown), via an unspecified route, administered in arm left on 23Jul2021 as DOSE 1, SINGLE for covid-19 immunization. The patient's medical history and concomitant medications were not reported. The patient previously received flu vaccine on an unspecified date and experienced Guillain-Barre (about six years ago). On an unspecified date in 2021, reported as for last ten days, the patient experienced aching in her bones/ bone aches. The patient also experienced muscle pain and joint pain. Investigation assessment was not reported. The outcome of the events was unknown.  Follow-up attempts are completed. No further information is expected.
Severe headache with very high fever spiking repeatedly to 104.5 orally over 4 day period, chills and sweats, on fifth day, fever blisters (?) along inside of top and bottom lips / decreased fever but dry heaves after bath.  No appetite throughout illness.  Assume recovered.
Patient received booster somewhere else and we got notified late. We administer Moderna covid vaccine too  Patient received Pfizer  1st- 1/12/21 2nd- 2/4/21 booster-9/21/21  Moderna Booster 11/5
Blood clots; sick; This is a spontaneous report from a contactable consumer. A female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE) as DOSE NUMBER UNKNOWN, SINGLE for COVID-19 immunisation. she had taken the vaccine and got sick and formed Blood Clots it made her very sick and it's not a Joke. Outcome of the events was unknown.  The lot number for [BNT162B2], was not provided and will be requested during follow up.
polymyalgia rheumatica; postherpetic neuralgia; shingles; Information has been received from a lawyer referring to a patient of unknown age and gender regarding a case in litigation. Information about concurrent condition, history condition and concomitant medication was not reported. In or around July 2013, the patient was vaccinated with zoster vaccine live (ZOSTAVAX) (strength, dose, route, lot# and expiration date unknown) for routine health maintenance and for its intended purpose: the prevention of shingles (herpes zoster). Shortly after receiving zoster vaccine live (ZOSTAVAX), the patient suffered shingles, postherpetic neuralgia and polymyalgia rheumatica. As a direct and proximate result of zoster vaccine live (ZOSTAVAX), the patient's symptoms have resulted in physical limitations not present prior to using the vaccine. The patient also experiences mental and emotional distress due to resulting physical limitations and seriousness of the patient's condition. As a result of the manufacture, marketing, advertising, promotion, distribution and/or sale of zoster vaccine live (ZOSTAVAX), the patient sustained severe and permanent personal injuries. Further, as a tragic consequence of zoster vaccine live (ZOSTAVAX), the patient suffered serious, progressive, permanent, and incurable injuries, as well as significant conscious pain and suffering, mental anguish, emotional distress, loss of enjoyment of life, physical impairment and injury. As a direct and proximate result of zoster vaccine live (ZOSTAVAX), the patient has suffered and incurred damages, including medical expenses; the loss of accumulations; and other economic and non-economic damages. The outcome of the events shingles, postherpetic neuralgia and polymyalgia rheumatica was considered to be not recovered and causal relationship was assessed as related.    The lawyer considered the events shingles, postherpetic neuralgia and polymyalgia rheumatica to be disability.   Upon internal review, polymyalgia rheumatica was determined to be medically significant.
On 4/9/2021 patient had odd sensation / chest pain unlike seizure or migraine pain and went to emergency room.  Was evaluated and released same day and told to follow up with neurologist.  On 4/10/2021 patient became dizzy and fell and hit her head.  She was unconscious of a few minutes.  On 4/11/2021 patient had speech issues and muscle issues (cramping and spasms).  All symptoms resolved by next day.  Evaluated by neurologist  4/15/2021.  Patient was told they thought symptoms were related to migraines and she is scheduled for MRI.
July 1st had a week of spotting. Then had a really heavy painful menstrual cycle at the end of July. Typically, my cycles are predictable and it rack them via an app. Now, 8/1 same pattern. Spotting and cramping. This is completely unusual and there have been no other major changes aside from the vaccine.
Red, swollen upper right arm, hives, red streak from site of injection, gave Benadryl.
Shingles, rash on right side of back, broke out 9 days after vaccine was administered. Initial diagnosis performed by video. Subsequent appointment in-person at a medial practice clinic with visit by dermatologist at a point when rash was resolving. Photographs available (4/16/2021)
? pt, after receiving immunizations, pt started with itching over body, shortness of breath with wheezing. Pt was given Xopenex 0.63mg viz nebulizer, Benadryl 15mg Prolone. Pt sent to ER.
This is a spontaneous report from a 54 year old female pt and follow-up from her physician. The pt received her 1st dose of Lymerix on 5/28/1999. Afterward, she experienced mild joint pain. On 6/29/1999, she received the 2nd dose of Lymerix and afterward she experienced joint pain, nausea, a bulls-eye rash on her arm, a knot above her injected elbow and she was weak and unable to lift her arm. Aspirin was taken for the headache. On 7/13/99, the pt was treated with prednisone. The most recent information received on 8/11/99 does not provide an outcome.
then had a stroke; This is a spontaneous report from a contactable consumer. A female patient (mother) of an unspecified age (Age: 87; Unit: Unknown) received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE; lot number and expiry date: unknown), via an unspecified route of administration on 23Jan2021 as single dose for COVID-19 immunization. The patient medical history and concomitant medications were not reported. The patient received the first dose of the pfizer covid 19 vaccine and then had a stroke on an unspecified date. Reporter wanted to know the maximum amount of time between the first and second dose. The outcome of the event was unknown.  Information on the lot/batch number has been requested.
fatigue, low - grade fever, slight chills, body aches hive - like rash / welt on injection site on Thursday morning, after getting shot on Tuesday afternoon